No reference-scaling for NTIDs [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2021-08-02 16:57 (481 d 18:20 ago) – Posting: # 22498
Views: 1,589

Hi Prasad,

❝ Little bit confusion raised as the Gliclazide is a NTI molecule, what would be the study design for gliclazide 80mg tablet BE study for Europe, WHO & HKG submission.


If you are referring to Hong Kong, guidances of China’s CDE are applicable.

Adding to what vixen wrote: Reference-scaling (ABEL: the EMA, most jurisdictions including the WHO or RSABE: U.S. FDA and China’s CDE) for NTIDs is not acceptable.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,417 posts in 4,692 threads, 1,596 registered users;
12 visitors (0 registered, 12 guests [including 9 identified bots]).
Forum time: 10:17 CET (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5